Linerase Officially Launches in Malaysia

Redefining Natural Skin Regeneration with Collagen Biostimulation

KUALA LUMPUR, Malaysia, May 21, 2025 /PRNewswire/ -- Linerase, the advanced collagen biostimulator trusted by aesthetic doctors worldwide, has officially launched in Malaysia. Designed to stimulate the body's natural collagen production, Linerase, a product distributed by Venusys Medical, offers a revolutionary approach to skin rejuvenation, restoring elasticity, firmness, and youthful radiance through scientifically backed biostimulation.

During the launch event, international expert Professor Andrea Corbo, Founder of Linerase and Dermatologist from Italy and Dr. Katerina Gkouvi, Dermatologist from Greece shared valuable insights into the science behind Linerase and its unique applications. The programme concluded with Dr. Lim Ting Song, aesthetic physician and Medical Director at Clique Clinic presenting results from local clinical trials, highlighting significant improvements in skin quality, elasticity, and resilience following treatment with Linerase.

Science Behind Linerase

Unlike traditional treatments that add volume or temporarily mask aging, Linerase directly targets the fibroblasts of our skin, which are essentially the cells that act as collagen factories within the skin. Upon being exposed to Linerase, these fibroblasts are stimulated to multiply themselves. Furthermore, Linerase also provides amino acids to these newly-formed fibroblasts, which are utilized as raw materials in the formation of new collagen. All of these effects work in tandem to significantly enhance the production of Type III collagen within our skin. This process helps restore skin firmness, improve texture, and support long-term skin regeneration. Its key indications include:

• Restoring skin elasticity and firmness in the face, neck, décolletage, and other body areas
• Improving atrophic skin conditions such as stretch marks, acne scars, post-surgical scars, and trauma lesions

Formulated with Heterologous Type I Collagen (HTIC) derived from equine sources, Linerase breaks down into amino acids and tripeptides upon hydrolysis. The tripeptides stimulate the formation of new fibroblasts and inhibit collagen-degrading enzymes, while the amino acids support the production of Type III collagen. This results in exceptional biocompatibility, promotes effective wound healing, and supports dermo-epidermal regeneration — all while maintaining a strong safety profile with no reported immune responses to date.

Linerase stands out in the field of regenerative aesthetics by stimulating the production of Type III collagen — a critical component in tissue repair, skin elasticity, and neovascularization. Its uniquely low molecular weight formulation (under 1 kiloDalton) significantly reduces the risk of allergenic reactions and granuloma formation, remaining well below the 10 kiloDalton threshold typically associated with such responses. Unlike many collagen stimulators that primarily target Type I collagen — which can lead to thicker, more fibrotic tissue — Linerase promotes the regeneration of Type III collagen, closely associated with youthful, resilient skin. This targeted approach results in more natural, supple outcomes, reinforcing Linerase's position as a safer and more advanced solution in aesthetic medicine.

"At Linerase, we believe that true skin rejuvenation lies not in covering up imperfections but in restoring the skin's natural structure and vitality. With Linerase, we are empowering the skin to heal, regenerate, and reveal its healthiest state," said Prof. Andrea Corbo during his sharing session.

Echoing this sentiment, Dr. Katerina shared, "Linerase fills an important gap in modern aesthetic medicine — offering patients a treatment that not only addresses visible signs of aging but does so in a way that is safe, natural, and scientifically backed. It's a new chapter for skin health in Malaysia."

A New Standard in Skin Health

Backed by over 30 years of research from its Italian developer CSD, and certified with ISO 9001 and ISO 13485 standards, Linerase stands at the forefront of regenerative aesthetics. Its scientifically proven efficacy, biocompatibility, and long-lasting natural results set a new benchmark in non-invasive skin rejuvenation.

For more information about Linerase, visit www.linerase.com.

About LINERASE

Linerase is a collagen biostimulator treatment developed by CSD, an Italian company founded in 1997 with a strong heritage in science, research, and aesthetic medicine. Certified with ISO 9001 and ISO 13485, CSD has dedicated the last three decades to advancing dermal biorevitalization technologies, specializing in innovative formulations using native Type I Collagen.

At the heart of Linerase is a commitment to slowing down the aging process by naturally regenerating the skin's structure, improving firmness, texture, and radiance. Designed to repair and reverse visible signs of skin aging, Linerase offers a cutting-edge approach to aesthetic treatments by stimulating the body's own collagen production.

Driven by a passion for science and creativity, CSD continues to invest heavily in research and development, expanding its product portfolio in dermal biostimulation and anti-aging solutions. Through global distribution networks, continuous practitioner education, and a strong focus on safety and innovation, Linerase is consolidating its position as a leader in the bioregeneration market worldwide. At Linerase, science meets artistry — offering safe, effective, and natural results for healthier, more youthful skin.

About Venusys Medical

Venusys Medical was incorporated since 2005. The company has since been the pioneer in the distribution of laser , light-based equipment and other multi-technology systems for the aesthetic and surgical markets. We pride ourselves in having all our medical equipment registered and approved by the Ministry of Health Malaysia to meet the stringent demand of the medical industry. Our portfolio focuses on two divisions – Aesthetic equipment and life science research products. We consistently discover new ways to address some of society's most challenging aesthetic issues.

Our mission is to serve the growing needs of both patients and practitioners. Venusys Medical has strong market positions in the areas of aesthetic dermatology, cosmetics & plastic surgery. We actively market our products to most of the hospitals, private medical centres, and aesthetic physician offices in Malaysia.

Website:                www.linerase.com
Facebook:             www.facebook.com/profile.php?id=61556731348025
Instagram:             www.instagram.com/linerase_sgmy

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Linerase Officially Launches in Malaysia

BEIJING, Jan. 11, 2026 /PRNewswire/ -- On December 29, the "Forging the Path to National Strength: China's Manufacturing Achievements Under the 14th Five-Year Plan," jointly organized by the National Museum of China and the Ministry of Industry and Information Technology, officially opened at the National Museum of China, showcasing more than 300 top national achievements. GAC's "National Outstanding Engineer Team" successfully developed both the Magazine Battery and the Solid-State Battery, which were selected for the exhibition.

The GAC Magazine Battery is the first battery system to pass both the nail penetration no-flame and non-ignition safety tests. By utilizing ultra-high intrinsic safety cells, an all-weather "vehicle-end + cloud-based" active safety monitoring system, and a multi-dimensional safety protection system, the Magazine Battery achieves three layers of protection: core, active, and passive. Its safety performance far exceeds the electric vehicles traction battery safety requirements (GB38031-2025), which will take effect on July 1, 2026. Currently, the Magazine Battery has a cumulative deployment of 1.3 million vehicles with zero spontaneous combustion and over 50 billion kilometers of safe travel, providing users with robust safety assurance for every journey.

GAC's self-developed large-capacity solid-state battery has achieved an energy density exceeding 400 Wh/kg and easily passes rigorous safety tests such as 200°C thermal chamber and nail penetration tests, effectively addressing users' range anxiety and safety concerns. Innovations in materials and processes have placed the solid-state battery at the forefront of the industry in key indicators such as safety, energy density, and cycle life, providing a superior power solution for the future development of NEVs. Currently, a pilot production line for GAC's solid-state battery has been established, capable of mass-producing vehicle-grade solid-state batteries over 60 Ah, marking a critical step toward the goal of full vehicle integration by 2026.

Over the years, GAC has been steadily enhancing its competitiveness through innovations across intelligent connectivity, NEV powertrains technologies, and forward-looking technologies. Looking ahead, GAC will continue to deepen its efforts in the intelligent connected NEV field, leveraging more leading technological achievements to drive industry progress.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

GAC Magazine Battery and Solid-State Battery Win Top National Honor